Canada Issues Renewed Warning Over Chantix

Law360, New York (January 7, 2009, 12:00 AM EST) -- Canadian health officials are reiterating their concerns over Pfizer Inc.'s smoking-cessation drug Chantix as they mull further strengthening the drug's labeling to address the risk of serious adverse psychiatric effects that have been associated with it.

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, said Tuesday that Canadians using or thinking of using Champix — as the drug is known in Europe and Canada — should be “aware of any unusual thoughts, feelings or behaviors, especially those related to depression,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.